Yesterday, Gilead Sciences (GILD) announced better-than-forecast earnings but full-year sales guidance that fell short of analyst predictions, causing its shares to tumble. As result, expectations for ...
- Zacks•2 days ago
Medical stocks are once again expected be among the better performers in Q2. Johnson & Johnson (JNJ) and Biogen have already set the tone with beats and raised outlooks.
|Bid||62.42 x 100|
|Ask||62.47 x 200|
|52wk Range||26.41 - 63.35|
|Day's Range||62.27 - 62.97|
|Avg Vol (3m)||2,749,179|
As of 10:39 AM EDT. NasdaqGS Real Time Price. Market open.